FDA grants orphan drug status to PEP-010 for pancreatic cancer
The U.S. Food and Drug Administration (FDA) has granted orphan drug status to Pep-Therapy‘s PEP-010, a potential first-in-class treatment for pancreatic cancer. The…
News
Repurposed avapritinib reduced tumor size in hard-to-treat gliomas
Avapritinib, an approved orally available medication, reduced tumor size in a subset of children and young adults with treatment-resistant high-grade gliomas, a study shows.
MIRASOL: Elahere extends survival in hard-to-treat ovarian cancer
Treatment with AbbVie’s Elahere (mirvetuximab soravtansine) reduced the risk of death by 32% in women with difficult-to-treat epithelial ovarian cancer over standard chemotherapy. That’s according…
2nd Iceland Cycling Expedition aims to raise myeloma research funds
The International Myeloma Foundation (IMF) has announced its 2nd annual Iceland Cycling Expedition (ICE), a seven-day endurance bike ride to raise funds for…
Treatment, outcomes poorer in AML with chromosome abnormality
Chromoanagenesis — an abnormal rearrangement of DNA within the chromosomes of certain cells, including blood cells — links with limited treatment response and poorer outcomes…
OSE2101 vaccine shows ‘promising benefit’ in pancreatic cancer trial
Treatment with the experimental cancer vaccine OSE2101, given in combination with standard chemotherapy, led to positive early results in a Phase 2 clinical trial…
LAM561 as add-on may delay glioblastoma disease progression
Adding the investigational therapy LAM561 to standard of care treatment may delay disease progression or death in people with newly diagnosed glioblastoma whose tumors exhibit…
Study of NKT3964 in gynecological, other cancers advances
A Phase 1 clinical trial testing Nikang Therapeutics’ oral therapy NKT3964 in people with certain advanced or metastatic solid tumors, including gynecological cancers,…
Use of dexamethasone may manage Tecvayli’s immune side effect: Study
The use of dexamethasone alone may successfully treat the immune side effect cytokine release syndrome (CRS) in people with relapsed or refractory multiple…
Olverembatinib named ALL breakthrough therapy in China
China has granted breakthrough therapy designation to olverembatinib to be used with low-intensity chemotherapy as a first-line treatment for newly diagnosed people with Philadelphia chromosome-positive…
